The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic

J Am Acad Dermatol. 2020 Aug;83(2):677-679. doi: 10.1016/j.jaad.2020.05.035. Epub 2020 May 19.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Betacoronavirus / immunology*
  • Biological Products / adverse effects*
  • COVID-19
  • Clinical Decision-Making*
  • Clinical Trials, Phase III as Topic
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / immunology*
  • Coronavirus Infections / prevention & control
  • Coronavirus Infections / virology
  • Humans
  • Interleukin-17 / antagonists & inhibitors*
  • Interleukin-17 / immunology
  • Interleukin-17 / metabolism
  • Pandemics / prevention & control
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / immunology*
  • Pneumonia, Viral / prevention & control
  • Pneumonia, Viral / virology
  • Psoriasis / drug therapy*
  • Psoriasis / immunology
  • Risk Assessment
  • SARS-CoV-2
  • Signal Transduction / drug effects
  • Signal Transduction / immunology

Substances

  • Biological Products
  • Interleukin-17